Live Breaking News & Updates on Intracoronary gene therapy

Stay informed with the latest breaking news from Intracoronary gene therapy on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Intracoronary gene therapy and stay connected to the pulse of your community

AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure

AB-1002 is being studied for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms

United-states , American , Canwen-jiang , Christian-rommel , Centers-for-disease , Drug-administration , Asklepios-biopharmaceutical-inc , Bayer-ag , American-heart-association , Head-of-research , Fast-track-program , Bayer-pharmaceuticals-division

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , North-carolina , United-states , Spain , Gipuzkoa , Pais-vasco , University-of-north-carolina , Berlin , Germany , Edinburgh , City-of , Research-triangle-park

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number...

University-of-north-carolina , North-carolina , United-states , Berlin , Germany , Research-triangle-park , Edinburgh , City-of , United-kingdom , Gipuzkoa , Pais-vasco , Spain

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

United-states , American , Timothyd-henry , Christian-rommel , Rogerj-hajjar , Head-of-research , American-heart-association-scientific-sessions , York-heart-association , Bayer-ag , Asklepios-biopharmaceutical-inc , Steering-committee-member , Asklepios-biopharmaceutical

First Patient Randomized In Askbio Phase II Gene Therapy Trial For Congestive Heart Failure

First Patient Randomized In Askbio Phase II Gene Therapy Trial For Congestive Heart Failure
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

University-of-north-carolina , North-carolina , United-states , Gipuzkoa , Pais-vasco , Spain , Research-triangle-park , Germany , United-kingdom , Berlin , Edinburgh , City-of

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic cardiomyopathy

United-states , American , Jude-samulski , Roger-hajjar , Lothar-roessig , Asklepios-biopharmaceutical-inc , American-heart-association , Centers-for-disease , Product-team-lead , Global-public-health-burden-of-heart-failure , York-heart-association , Bayer-ag